Alpha Cognition Expands Commercial and Medical Teams with Key Leadership Hires to Support the Launch of ZUNVEYL
Alpha Cognition (NASDAQ: ACOG) has announced strategic appointments to strengthen its commercial and medical teams ahead of the ZUNVEYL launch, its treatment for mild to moderate Alzheimer's disease, planned for Q1 2025. The company has appointed:
- Jen Pesa as VP of Commercial, bringing 25 years of pharmaceutical experience and 12 successful product launches
- Jack Kelly as Head of Market Access, with 30+ years in pharmaceutical industry
- Rommel Fernandez as VP of Corporate Strategy and Operations, with 17 years of experience in pharma and biotech
- Kurt Grady as VP of Medical Affairs, bringing 30 years of healthcare experience
These appointments aim to build the commercial infrastructure necessary for ZUNVEYL's nationwide pharmacy launch, with particular focus on the long-term care (LTC) segment.
Alpha Cognition (NASDAQ: ACOG) ha annunciato nomine strategiche per rafforzare i suoi team commerciali e medici in previsione del lancio di ZUNVEYL, il suo trattamento per l'Alzheimer da lieve a moderato, previsto per il primo trimestre del 2025. L'azienda ha nominato:
- Jen Pesa come VP Commerciale, che porta con sé 25 anni di esperienza nel settore farmaceutico e 12 lanci di prodotti di successo
- Jack Kelly come Responsabile dell'Accesso al Mercato, con oltre 30 anni di esperienza nell'industria farmaceutica
- Rommel Fernandez come VP della Strategia Aziendale e delle Operazioni, con 17 anni di esperienza nel settore farmaceutico e biotecnologico
- Kurt Grady come VP degli Affari Medici, con 30 anni di esperienza nel settore sanitario
Queste nomine mirano a costruire l'infrastruttura commerciale necessaria per il lancio nazionale di ZUNVEYL nelle farmacie, con particolare attenzione al segmento delle cure a lungo termine (LTC).
Alpha Cognition (NASDAQ: ACOG) ha anunciado nombramientos estratégicos para fortalecer sus equipos comerciales y médicos antes del lanzamiento de ZUNVEYL, su tratamiento para la enfermedad de Alzheimer leve a moderada, programado para el primer trimestre de 2025. La compañía ha nombrado:
- Jen Pesa como VP Comercial, que aporta 25 años de experiencia farmacéutica y 12 lanzamientos de productos exitosos
- Jack Kelly como Jefe de Acceso al Mercado, con más de 30 años en la industria farmacéutica
- Rommel Fernandez como VP de Estrategia Corporativa y Operaciones, con 17 años de experiencia en farmacéutica y biotecnología
- Kurt Grady como VP de Asuntos Médicos, que aporta 30 años de experiencia en el sector de la salud
Estos nombramientos tienen como objetivo construir la infraestructura comercial necesaria para el lanzamiento nacional de ZUNVEYL en farmacias, con un enfoque particular en el segmento de cuidado a largo plazo (LTC).
알파 코그니션 (NASDAQ: ACOG)은 2025년 1분기에 예정된 준벨 (ZUNVEYL) 출시를 앞두고 상업 및 의료 팀을 강화하기 위한 전략적 인사를 발표했습니다. 이 회사는 다음과 같이 임명했습니다:
- 제인 페사(Jen Pesa)를 상업 부문 부사장으로 임명, 제약 산업에서 25년의 경력과 12건의 성공적인 제품 출시 경험 보유
- 잭 켈리(Jack Kelly)를 시장 접근 책임자로 임명, 제약 산업에서 30년 이상의 경력 보유
- 롬멜 펀데스(Rommel Fernandez)를 기업 전략 및 운영 부사장으로 임명, 제약 및 생명공학 분야에서 17년의 경험 보유
- 커트 그래디(Kurt Grady)를 의료 부문 부사장으로 임명, 헬스케어 분야에서 30년의 경험 보유
이번 인사의 목적은 장기 요양(LTC) 부문에 특히 주목하여, 준벨의 전국 약국 출시를 위한 상업적 기반을 구축하는 것입니다.
Alpha Cognition (NASDAQ: ACOG) a annoncé des nominations stratégiques pour renforcer ses équipes commerciales et médicales en vue du lancement de ZUNVEYL, son traitement pour la maladie d'Alzheimer léger à modéré, prévu pour le premier trimestre 2025. La société a nommé :
- Jen Pesa au poste de VP Commercial, apportant 25 ans d'expérience dans l'industrie pharmaceutique et 12 lancements de produits réussis
- Jack Kelly en tant que Responsable de l'Accès au Marché, avec plus de 30 ans d'expérience dans l'industrie pharmaceutique
- Rommel Fernandez comme VP de la Stratégie et des Opérations, avec 17 ans d'expérience en pharma et biotechnologie
- Kurt Grady au poste de VP des Affaires Médicales, apportant 30 ans d'expérience dans le secteur de la santé
Ces nominations visent à construire l'infrastructure commerciale nécessaire pour le lancement national de ZUNVEYL dans les pharmacies, en se concentrant particulièrement sur le segment des soins de longue durée (LTC).
Alpha Cognition (NASDAQ: ACOG) hat strategische Neubesetzungen angekündigt, um seine Verkaufs- und Medizinteams vor dem geplanten Launch von ZUNVEYL, einer Behandlung für leichte bis mittelschwere Alzheimer-Krankheit, der für das erste Quartal 2025 vorgesehen ist, zu stärken. Das Unternehmen hat folgende Personen ernannt:
- Jen Pesa zur VP für Vertrieb, die 25 Jahre Erfahrung in der Pharmaindustrie und 12 erfolgreiche Produkteinführungen mitbringt
- Jack Kelly zum Leiter des Marktzugangs, mit über 30 Jahren Erfahrung in der Pharmaindustrie
- Rommel Fernandez zum VP für Unternehmensstrategie und Betrieb, mit 17 Jahren Erfahrung in der Pharma- und Biotech-Branche
- Kurt Grady zum VP für Medizinische Angelegenheiten, mit 30 Jahren Erfahrung im Gesundheitswesen
Diese Ernennungen zielen darauf ab, die notwendige kommerzielle Infrastruktur für den landesweiten Launch von ZUNVEYL in Apotheken aufzubauen, mit besonderem Fokus auf den Bereich der Langzeitpflege (LTC).
- Strategic expansion of leadership team with extensive industry experience
- Clear launch timeline for ZUNVEYL set for Q1 2025
- Strong focus on long-term care market segment
- New executives bring successful track record in product launches and market access
- None.
Ms. Pesa brings 25 years of pharmaceutical commercial leadership to Alpha Cognition. Jen has successfully launched 12 products across 13 therapeutic areas, including neurology, psychiatry, and in multiple geriatric markets. With 14 years dedicated to long-term care (LTC), she has a deep understanding of this complex segment and a proven track record in building strategies that improve patient outcomes while enhancing healthcare delivery. Her expertise in driving cross-functional collaboration across marketing, market access, and sales operations will be instrumental in establishing the commercial success of ZUNVEYL.
Mr. Kelly brings over 30 years of experience in roles of increasing responsibility in the pharmaceutical industry with Bristol-Myers Squibb, Daiichi Sankyo (DSI), and most recently Arbor Pharmaceuticals. He has successfully developed and implemented market access launch strategies, while growing numerous products in the CNS and 505(B)(2) space. Additionally, he has led strategic account management and contract negotiations with key payers, including Medicare, by delivering value-added solutions and services to customers and patients.
Mr. Fernandez is a commercial strategy executive with over 17 years of experience driving growth and innovation in the pharmaceutical and biotechnology industries. He has played a pivotal role in the commercialization and launch of six pharmaceutical products, delivering measurable outcomes for patients, providers, and stakeholders. As Chief Analytics Officer at Fingerpaint Group, Rommel led the integration of advanced analytics and generative AI into business operations. At La Jolla Pharmaceutical, he was instrumental in the launch of Giapreza, securing over 300 formulary approvals, access into some of the most high control health systems, and increasing hospital reimbursements for Medicare patients. His expertise spans market access, commercialization, financial modeling, and lifecycle management, consistently contributing to organizational growth and market success.
Dr. Grady has over 30 years of experience in health care, with a strong background in both clinical practice and the life science industry. He possesses broad therapeutic experience and has supported the launch of 9 new products and new indications in that time. Prior to joining Alpha Cognition, Kurt was Executive Director of Field Medical, Medical Operations, and Medical Communications at Reneo Pharmaceuticals. During his tenure at Reneo, he was instrumental in building the Medical Affairs team and infrastructure and preparing for product launch. Prior to that, Kurt served as Head of US Medical Affairs at Acacia Pharma, Inc., and built and led the Medical Affairs organization through the successful launch of two new products. His pharmacy clinical practice experience includes Cox Health Systems in
“We are thrilled to welcome Jen, Rommel, Jack, and Kurt to the Alpha Cognition team as we build our commercial infrastructure for the upcoming launch of ZUNVEYL in Q1 2025,” said Lauren D’Angelo, COO of Alpha Cognition. “Their extensive experience in long-term care, coupled with their functional expertise in commercial leadership, market access, data analytics and operational excellence, and medical expertise in LTC, will be critical as we bring this innovative treatment to patients with Alzheimer’s disease. This leadership team is already working hand-in-hand, and I’m confident that their leadership will drive impactful results and set new benchmarks for success in our journey.”
With these key hires, Alpha Cognition is poised to advance its mission of improving the lives of patients and families affected by neurodegenerative diseases. ZUNVEYL will be available by prescription in pharmacies nationwide in Q1 2025.
About Alpha Cognition Inc.
Alpha Cognition Inc. is a commercial stage, biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer’s disease and Cognitive Impairment with mild Traumatic Brain Injury (“mTBI”), for which there are currently no approved treatment options.
ZUNVEYL is a patented drug approved as a new generation acetylcholinesterase inhibitor (AChEI) for the treatment of Alzheimer’s disease, with expected minimal gastrointestinal side effects. ZUNVEYL’s active metabolite is differentiated from donepezil and rivastigmine in that it improves the function of neuronal nicotinic receptors, most notably the alpha-7 subtype, which is known to have a positive effect on cognition. Benzgalantamine is also being developed in combination with memantine to treat moderate to severe Alzheimer’s dementia, and as an intranasal formulation for Cognitive Impairment with mTBI.
Forward-looking Statements
This news release includes forward-looking statements within the meaning of applicable securities laws. Except for statements of historical fact, any information contained in this news release may be a forward-looking statement that reflects the Company’s current views about future events and are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. In some cases, you can identify forward-looking statements by the words “may,” “might,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “objective,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “target,” “seek,” “contemplate,” “continue” and “ongoing,” or the negative of these terms, or other comparable terminology intended to identify statements about the future. Forward-looking statements may include statements regarding Ms. Pesa’s appointment as Vice President of Commercial, Mr. Kelly’s appointment as Head of Market Access, Mr. Fernandez’s appointment of Vice President of Corporate Strategy and Operations, Dr. Grady’s appointment as Vice President of Medical Affairs, and the current or future efficacy of ZUNVEYL as an innovative treatment for Alzheimer’s disease. Although the Company believes to have a reasonable basis for each forward-looking statement, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain. The Company cannot assure that the actual results will be consistent with these forward-looking statements. These forward-looking statements speak only as of the date of this news release and the Company undertakes no obligation to revise or update any forward-looking statements for any reason, even if new information becomes available in the future.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250114415859/en/
For further information:
Michael McFadden, CEO
info@alphacognition.com
Source: Alpha Cognition Inc.
FAQ
When will Alpha Cognition (ACOG) launch ZUNVEYL for Alzheimer's disease?
Who are the new key executives joining Alpha Cognition (ACOG) for the ZUNVEYL launch?
What experience does Jen Pesa bring to Alpha Cognition (ACOG)?
How is Alpha Cognition (ACOG) preparing for the commercial launch of ZUNVEYL?
